$FBLG
FibroBiologics, Inc. Stock $fblg

$fblg Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000149315224044736 Filed on November 12, 2024

Income Statement

Concept	2024 Q4	2024 Q3	2023 Q3
Revenue		$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin		$2.139M	$1.477M
YoY Change		44.82%	48.74%
% of Gross Profit
Research & Development		$1.213M	$574.0K
YoY Change		111.32%	64.94%
% of Gross Profit
Depreciation & Amortization		$38.00K	$13.00K
YoY Change		192.31%
% of Gross Profit
Operating Expenses		$3.352M	$2.051M
YoY Change		63.43%	52.95%
Operating Profit		-$3.352M	-$2.052M
YoY Change		63.35%
Interest Expense		$74.00K	$0.00
YoY Change			-100.0%
% of Operating Profit
Other Income/Expense, Net		$2.852M	-$141.0K
YoY Change		-2122.7%
Pretax Income		-$500.0K	-$2.192M
YoY Change		-77.19%	40.33%
Income Tax
% Of Pretax Income
Net Earnings		-$500.0K	-$2.192M
YoY Change		-77.19%	40.33%
Net Earnings / Revenue
Basic Earnings Per Share		-$0.01	-$0.08
Diluted Earnings Per Share		-$0.01	-$0.07
COMMON SHARES
Basic Shares Outstanding	34.66M shares	35.16M shares	28.23M shares
Diluted Shares Outstanding		33.52M shares	28.23M shares

Balance Sheet

Concept	2024 Q3	2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$7.827M	$10.77M
YoY Change	-27.3%
Cash & Equivalents	$7.827M	$10.77M
Short-Term Investments
Other Short-Term Assets	$18.00K	$148.0K
YoY Change	-87.84%
Inventory
Prepaid Expenses	$353.0K
Receivables
Other Receivables
Total Short-Term Assets	$8.198M	$10.91M
YoY Change	-24.89%
LONG-TERM ASSETS
Property, Plant & Equipment	$772.0K	$2.385M
YoY Change	-67.63%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$2.271M	$2.385M
YoY Change	-4.78%
TOTAL ASSETS
Total Short-Term Assets	$8.198M	$10.91M
Total Long-Term Assets	$2.271M	$2.385M
Total Assets	$10.47M	$13.30M
YoY Change	-21.28%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.179M	$820.0K
YoY Change	43.78%
Accrued Expenses	$392.0K	$353.0K
YoY Change	11.05%
Deferred Revenue	$241.0K
YoY Change
Short-Term Debt	$115.0K	$0.00
YoY Change		-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$6.677M	$1.314M
YoY Change	408.14%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$1.055M	$1.447M
YoY Change	-27.09%
Total Long-Term Liabilities	$1.055M	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.677M	$1.314M
Total Long-Term Liabilities	$1.055M	$0.00
Total Liabilities	$7.732M	$2.761M
YoY Change	180.04%
SHAREHOLDERS EQUITY
Retained Earnings	-$32.42M
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$2.737M	$10.54M
YoY Change
Total Liabilities & Shareholders Equity	$10.47M	$13.30M
YoY Change	-21.28%

Cashflow Statement

Concept	2024 Q3	2023 Q3
OPERATING ACTIVITIES
Net Income	-$500.0K	-$2.192M
YoY Change	-77.19%	40.33%
Depreciation, Depletion And Amortization	$38.00K	$13.00K
YoY Change	192.31%
Cash From Operating Activities	-$2.606M	-$1.139M
YoY Change	128.8%	-16.68%
INVESTING ACTIVITIES
Capital Expenditures	$11.00K	$413.0K
YoY Change	-97.34%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$11.00K	-$413.0K
YoY Change	-97.34%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	4.471M	940.0K
YoY Change	375.64%	-413.33%
NET CHANGE
Cash From Operating Activities	-2.606M	-1.139M
Cash From Investing Activities	-11.00K	-413.0K
Cash From Financing Activities	4.471M	940.0K
Net Change In Cash	1.854M	-612.0K
YoY Change	-402.94%	-63.29%
FREE CASH FLOW
Cash From Operating Activities	-$2.606M	-$1.139M
Capital Expenditures	$11.00K	$413.0K
Free Cash Flow	-$2.617M	-$1.552M
YoY Change	68.62%	13.53%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7827000	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	8198000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	9215000	usd
CY2024Q3	us-gaap	Assets Assets	10469000	usd
CY2023Q4	us-gaap	Assets Assets	11821000	usd
CY2024Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1179000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1444000	usd
CY2023Q4	FBLG	Parent Company Payable ParentCompanyPayable	141000	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	392000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	362000	usd
CY2024Q3	FBLG	Commitment Fee Payable CommitmentFeePayable	1863000	usd
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001958777
CY2023Q4	FBLG	Commitment Fee Payable CommitmentFeePayable		usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent		usd
CY2023Q4	FBLG	Warrant Liability WarrantLiability		usd
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent		usd
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-41934
	dei	Entity Registrant Name EntityRegistrantName	FibroBiologics, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	86-3329066
	dei	Entity Address Address Line1 EntityAddressAddressLine1	455 E. Medical Center Blvd
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 300
	dei	Entity Address City Or Town EntityAddressCityOrTown	Houston
	dei	Entity Address State Or Province EntityAddressStateOrProvince	TX
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	77598
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	77598
	dei	City Area Code CityAreaCode	(281)
	dei	Security12b Title Security12bTitle	Common Stock, $0.00001 par value
	dei	Trading Symbol TradingSymbol	FBLG
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	34659125	shares
	dei	Entity Listing Par Value Per Share EntityListingParValuePerShare	0.00001
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9163000	usd
CY2024Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	353000	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	36000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	16000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	772000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	797000	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1499000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1809000	usd
CY2024Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	241000	usd
CY2023Q4	FBLG	Liability Instrument LiabilityInstrument	7236000	usd
CY2024Q3	FBLG	Warrant Liability WarrantLiability	2887000	usd
CY2024Q3	us-gaap	Notes Payable Current NotesPayableCurrent	115000	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	6677000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	9183000	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1055000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1385000	usd
CY2024Q3	us-gaap	Liabilities Liabilities	7732000	usd
CY2024Q3	FBLG	Parent Company Payable ParentCompanyPayable		usd
CY2024Q3	FBLG	Liability Instrument LiabilityInstrument		usd
CY2024Q3	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q3	FBLG	Fair Value Adjustment Of Liability Instrument FairValueAdjustmentOfLiabilityInstrument		usd
	FBLG	Fair Value Adjustment Of Liability Instrument FairValueAdjustmentOfLiabilityInstrument		usd
CY2023Q3	FBLG	Fair Value Adjustment Of Forward Contract Liability FairValueAdjustmentOfForwardContractLiability		usd
	FBLG	Fair Value Adjustment Of Forward Contract Liability FairValueAdjustmentOfForwardContractLiability		usd
CY2024Q3	us-gaap	Debt Related Commitment Fees And Debt Issuance Costs DebtRelatedCommitmentFeesAndDebtIssuanceCosts		usd
CY2023Q3	us-gaap	Debt Related Commitment Fees And Debt Issuance Costs DebtRelatedCommitmentFeesAndDebtIssuanceCosts		usd
	us-gaap	Debt Related Commitment Fees And Debt Issuance Costs DebtRelatedCommitmentFeesAndDebtIssuanceCosts		usd
CY2023Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest		usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest		usd
CY2023Q3	us-gaap	Interest Expense Debt InterestExpenseDebt		usd
CY2024Q3	FBLG	Deemed Dividend DeemedDividend		usd
CY2023Q3	FBLG	Deemed Dividend DeemedDividend		usd
	FBLG	Deemed Dividend DeemedDividend		usd
CY2024Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
CY2024Q1	us-gaap	Stock Redeemed Or Called During Period Value StockRedeemedOrCalledDuringPeriodValue		usd
	FBLG	Fair Value Adjustment Of Liability Instrument FairValueAdjustmentOfLiabilityInstrument		usd
	FBLG	Fair Value Adjustment Of Forward Contract Liability FairValueAdjustmentOfForwardContractLiability		usd
	us-gaap	Derivative Loss On Derivative DerivativeLossOnDerivative		usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		usd
	FBLG	Increase Decrease In In Commitment Fee Payable IncreaseDecreaseInInCommitmentFeePayable		usd
	FBLG	Rofn Agreement Payments To Parent RofnAgreementPaymentsToParent		usd
	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable		usd
	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt		usd
	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt		usd
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock		usd
	FBLG	Proceeds From Issuance Of Preferred Stock And Preference Stock1 ProceedsFromIssuanceOfPreferredStockAndPreferenceStock1		usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	FBLG	Issuance Of Series B Preferred Stock For Conversion Of Notes And Accrued Interest IssuanceOfSeriesBPreferredStockForConversionOfNotesAndAccruedInterest		usd
	FBLG	Reclassification Of Derivative Liability For Conversion Of Notes To Series B Preferred Stock ReclassificationOfDerivativeLiabilityForConversionOfNotesToSeriesBPreferredStock		usd
	FBLG	Settlement Of Forward Contract Liability For Sale Of Shares To Gem Pursuant To Draw Down And Closing Notices SettlementOfForwardContractLiabilityForSaleOfSharesToGemPursuantToDrawDownAndClosingNotices		usd
CY2024Q3	FBLG	Deemed Dividend DeemedDividend		usd
CY2023Q3	FBLG	Deemed Dividend DeemedDividend		usd
	FBLG	Deemed Dividend DeemedDividend		usd
	dei	Document Type DocumentType	10-Q
	dei	Local Phone Number LocalPhoneNumber	651-5150
CY2024Q3	us-gaap	Other Assets Current OtherAssetsCurrent	18000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	10568000	usd
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	35156000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	25609000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-32419000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-24357000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	2737000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	1253000	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	10469000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11821000	usd
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1213000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	571000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3148000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1595000	usd
CY2024Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2139000	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1481000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6877000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4814000	usd
CY2024Q3	us-gaap	Operating Expenses OperatingExpenses	3352000	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	2052000	usd
	us-gaap	Operating Expenses OperatingExpenses	10025000	usd
	us-gaap	Operating Expenses OperatingExpenses	6409000	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3352000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2052000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-10025000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-6409000	usd
CY2024Q3	FBLG	Fair Value Adjustment Of Liability Instrument FairValueAdjustmentOfLiabilityInstrument	-1927000	usd
	FBLG	Fair Value Adjustment Of Liability Instrument FairValueAdjustmentOfLiabilityInstrument	-4349000	usd
CY2024Q3	FBLG	Fair Value Adjustment Of Forward Contract Liability FairValueAdjustmentOfForwardContractLiability	-849000	usd
	FBLG	Fair Value Adjustment Of Forward Contract Liability FairValueAdjustmentOfForwardContractLiability	650000	usd
	us-gaap	Debt Related Commitment Fees And Debt Issuance Costs DebtRelatedCommitmentFeesAndDebtIssuanceCosts	1941000	usd
CY2024Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2000	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-141000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	31000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-213000	usd
CY2024Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	79000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	188000	usd
CY2024Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	5000	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	14000	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	146000	usd
CY2024Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2852000	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-141000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1963000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-359000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-500000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-2193000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-8062000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-6768000	usd
	FBLG	Deemed Dividend DeemedDividend	-2573000	usd
CY2024Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-500000	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2193000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8062000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9341000	usd
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.08
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.25
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.33
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.33
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33516656	shares
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	33516656	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28230842	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	28230842	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	32457473	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	32457473	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28230842	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	28230842	shares
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	1253000	usd
CY2024Q1	FBLG	Stock Issued During Period Value Preferred Stock StockIssuedDuringPeriodValuePreferredStock	45000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2819000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	480000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-8460000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-3863000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	578000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	898000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-2387000	usd
CY2024Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	5052000	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	572000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-500000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	2737000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-3996000	usd
CY2023Q1	FBLG	Stock Issued During Period Value Sale Of Preferred Stock Net Of Direct Costs StockIssuedDuringPeriodValueSaleOfPreferredStockNetOfDirectCosts	4889000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	4286000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Dividend StockIssuedDuringPeriodValueStockDividend	2573000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	448000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2415000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	639000	usd
CY2023Q2	FBLG	Stock Issued During Period Value Sale Of Preferred Stock Net Of Direct Costs StockIssuedDuringPeriodValueSaleOfPreferredStockNetOfDirectCosts	10056000	usd
CY2023Q2	FBLG	Stock Issued During Period Value Sale Of Preferred Stock One Net Of Direct Costs StockIssuedDuringPeriodValueSaleOfPreferredStockOneNetOfDirectCosts	253000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	2117000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	448000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-2160000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	11353000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	11353000	usd
CY2023Q3	FBLG	Stock Issued During Period Value Sale Of Preferred Stock One Net Of Direct Costs StockIssuedDuringPeriodValueSaleOfPreferredStockOneNetOfDirectCosts	941000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	437000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-2193000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-2193000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	10538000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	10538000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-8062000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-6768000	usd
	FBLG	Fair Value Adjustment Of Liability Instrument FairValueAdjustmentOfLiabilityInstrument	-4349000	usd
	FBLG	Fair Value Adjustment Of Forward Contract Liability FairValueAdjustmentOfForwardContractLiability	650000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1675000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1333000	usd
	us-gaap	Derivative Loss On Derivative DerivativeLossOnDerivative	72000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	81000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	310000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	291000	usd
	us-gaap	Depreciation Depreciation	110000	usd
	us-gaap	Depreciation Depreciation	16000	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	317000	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-2000	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	2000	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	91000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-265000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	396000	usd
	FBLG	Increase Decrease In In Commitment Fee Payable IncreaseDecreaseInInCommitmentFeePayable	1863000	usd
	FBLG	Increase Decrease In Payable To Parent IncreaseDecreaseInPayableToParent	-141000	usd
	FBLG	Increase Decrease In Payable To Parent IncreaseDecreaseInPayableToParent	141000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-300000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-273000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8828000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4800000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	85000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	493000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-85000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-493000	usd
	FBLG	Rofn Agreement Payments To Parent RofnAgreementPaymentsToParent	2645000	usd
	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	300000	usd
	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	574000	usd
	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	459000	usd
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	14945000	usd
	FBLG	Proceeds From Issuance Of Preferred Stock And Preference Stock1 ProceedsFromIssuanceOfPreferredStockAndPreferenceStock1	1193000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	7462000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7577000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	13793000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1336000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	8500000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9163000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2266000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7827000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10766000	usd
	us-gaap	Interest Paid Net InterestPaidNet	14000	usd
	us-gaap	Interest Paid Net InterestPaidNet	1000	usd
	FBLG	Issuance Of Series B Preferred Stock For Conversion Of Notes And Accrued Interest IssuanceOfSeriesBPreferredStockForConversionOfNotesAndAccruedInterest	5866000	usd
	FBLG	Reclassification Of Derivative Liability For Conversion Of Notes To Series B Preferred Stock ReclassificationOfDerivativeLiabilityForConversionOfNotesToSeriesBPreferredStock	538000	usd
	FBLG	Settlement Of Forward Contract Liability For Sale Of Shares To Gem Pursuant To Draw Down And Closing Notices SettlementOfForwardContractLiabilityForSaleOfSharesToGemPursuantToDrawDownAndClosingNotices	409000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-32419000	usd
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7827000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2819000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2819000	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	4643000	usd
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2023Q4	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-4 shares
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_843_eus-gaap--UseOfEstimates_z7MDEP4GTOOe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zwEJVG7GUjhg">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the Unaudited Condensed Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Unaudited Condensed Financial Statements and the reported amounts of expenses during the reporting periods. These estimates are based on information available as of the date of the Unaudited Condensed Financial Statements; therefore, actual results could differ from those estimates and assumptions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_zIObZRkkrs6d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zseozDVPfphh">Concentration of Credit Risk</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company has significant cash balances at financial institutions, which, throughout the year, regularly exceed the federally insured limit of $<span id="xdx_90E_eus-gaap--CashFDICInsuredAmount_iI_pn3d_c20240930_z3NVG95ikkwh" title="Federally insured limit">250,000</span>. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company’s financial condition, results of operations and cash flows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q3	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2024Q3	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	6488000	usd
CY2023Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-500000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-2193000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-8062000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-6768000	usd
	FBLG	Deemed Dividend DeemedDividend	-2573000	usd
CY2024Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-500000	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2193000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8062000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9341000	usd
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33516656	shares
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	33516656	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28230842	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	28230842	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	32457473	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	32457473	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28230842	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	28230842	shares
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.08
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.25
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.25
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.33
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.33
CY2024Q3	FBLG	Stock Issued During Period Remaining Shares Issues StockIssuedDuringPeriodRemainingSharesIssues	741164	shares
CY2022Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	5600000	usd
CY2022Q4	us-gaap	Common Stocks Including Additional Paid In Capital CommonStocksIncludingAdditionalPaidInCapital	10000000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	929000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	844000	usd
CY2024Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	157000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	47000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	772000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	797000	usd
CY2024Q3	us-gaap	Depreciation Depreciation	38000	usd
CY2023Q3	us-gaap	Depreciation Depreciation	13000	usd
	us-gaap	Depreciation Depreciation	110000	usd
	us-gaap	Depreciation Depreciation	16000	usd
CY2024Q3	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	6488000	usd
CY2024Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	6488000	usd
CY2024Q3	FBLG	Forward Contract Liability ForwardContractLiability	241000	usd
CY2024Q3	us-gaap	Derivative Liabilities DerivativeLiabilities	2887000	usd
CY2024Q3	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	3128000	usd
CY2023Q4	FBLG	Liability Instrument Fair Value LiabilityInstrumentFairValue	7236000	usd
CY2023Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	7236000	usd
CY2023Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	7236000	usd
CY2024Q4	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	1000000	shares
CY2024Q4	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	258836	shares
CY2024Q3	FBLG	Stock Issued During Period Remaining Shares Issues StockIssuedDuringPeriodRemainingSharesIssues	741164	shares
CY2024Q3	us-gaap	Share Price SharePrice	3.25
CY2024Q3	FBLG	Floor Price FloorPrice	3.25
CY2024Q3	FBLG	Discount Percentage DiscountPercentage	0.10	pure
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2022	us-gaap	Stock Issued During Period Shares Employee Benefit Plan StockIssuedDuringPeriodSharesEmployeeBenefitPlan	51250	shares
CY2022	us-gaap	Employee Benefits And Share Based Compensation Noncash EmployeeBenefitsAndShareBasedCompensationNoncash	168000	usd
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	10000000	shares
	FBLG	Description Of Share Subscription Agreement DescriptionOfShareSubscriptionAgreement	The Company may request a drawdown, or sale of common stock shares to the investors, over the five-year term of this agreement following the public listing unless terminated earlier. The amount of the drawdowns requested is limited by the trading volumes of the Company’s common stock over the 30-day period preceding the drawdown, and the price per share is equal to 90% of the average price per share over that same period. A 1% fee was due to the investors if the Company were sold in a private sale transaction rather than completing a public listing of its shares.
CY2024Q1	FBLG	Commitment Fee Payable CommitmentFeePayable	2000000	usd
CY2024Q1	us-gaap	Debt Related Commitment Fees And Debt Issuance Costs DebtRelatedCommitmentFeesAndDebtIssuanceCosts	1941000	usd
CY2024Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	1600000	shares
CY2024Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	758000	usd
CY2024Q3	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	1600000	shares
CY2024Q3	us-gaap	Sale Of Stock Percentage Of Ownership Before Transaction SaleOfStockPercentageOfOwnershipBeforeTransaction	0.90	pure
CY2024Q3	us-gaap	Share Price SharePrice	4.74
CY2024Q3	FBLG	Discount Percentage DiscountPercentage	0.10	pure
CY2024Q3	us-gaap	Liabilities Related To Investment Contracts Fair Value Disclosure LiabilitiesRelatedToInvestmentContractsFairValueDisclosure	286000	usd
CY2024Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	100000	shares
CY2024Q3	us-gaap	Share Price SharePrice	1.65
CY2024Q3	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	4.51
CY2024Q3	FBLG	Discount Percentage DiscountPercentage	0.10	pure
CY2024Q3	us-gaap	Stock Issued During Period Shares Share Based Compensation Forfeited StockIssuedDuringPeriodSharesShareBasedCompensationForfeited	500000	shares
CY2024Q3	FBLG	Stock Issued During Period Remaining Shares Issues StockIssuedDuringPeriodRemainingSharesIssues	1000000	shares
CY2024Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	1000000	shares
CY2024Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	325000	usd
CY2024Q3	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	1000000	shares
CY2024Q3	us-gaap	Sale Of Stock Percentage Of Ownership Before Transaction SaleOfStockPercentageOfOwnershipBeforeTransaction	0.90	pure
CY2024Q3	us-gaap	Share Price SharePrice	3.25
CY2024Q3	FBLG	Floor Price FloorPrice	3.25
CY2024Q3	FBLG	Discount Percentage DiscountPercentage	0.10	pure
CY2024Q3	us-gaap	Liabilities Related To Investment Contracts Fair Value Disclosure LiabilitiesRelatedToInvestmentContractsFairValueDisclosure	57000	usd
CY2024Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	258836	shares
CY2024Q3	FBLG	Stock Price StockPrice	3.14
CY2024Q3	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	2.93
CY2024Q3	FBLG	Discount Percentage DiscountPercentage	0.10	pure
CY2024Q3	FBLG	Stock Issued During Period Remaining Shares Issues StockIssuedDuringPeriodRemainingSharesIssues	741164	shares
CY2024Q3	FBLG	Stock Issued During Period Remaining Shares Issues StockIssuedDuringPeriodRemainingSharesIssues	741164	shares
CY2024Q3	us-gaap	Share Price SharePrice	3.25
CY2024Q3	FBLG	Floor Price FloorPrice	3.25
CY2024Q3	FBLG	Discount Percentage DiscountPercentage	0.10	pure
	us-gaap	Payments For Rent PaymentsForRent	466000	usd
	us-gaap	Payments For Rent PaymentsForRent	504000	usd
CY2023Q3	us-gaap	Derivative Liabilities DerivativeLiabilities	2573000	usd
CY2023Q3	FBLG	Derivative Liabilities Payable To Related Parties DerivativeLiabilitiesPayableToRelatedParties	2645000	usd
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	101250	shares
CY2022Q3	us-gaap	Share Price SharePrice	3.28
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3689750	shares
CY2023Q1	us-gaap	Share Price SharePrice	2.28
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2500	shares
CY2023Q3	us-gaap	Share Price SharePrice	3.28
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	216875	shares
CY2024Q1	us-gaap	Share Price SharePrice	13.00
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	6875	shares
CY2024Q2	us-gaap	Share Price SharePrice	6.73
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	25000	shares
CY2024Q3	us-gaap	Share Price SharePrice	1.73
CY2024Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	8467889	shares
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	8711500	shares
CY2024Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	572000	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	440000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1631000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1333000	usd
CY2024Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	5766000	usd
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y7M6D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.037	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.043	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.039	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.97	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.01	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.90	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P7Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	9.70

Files In Submission

Name	View Source	Status
0001493152-24-044736-index-headers.html	Edgar Link	pending
0001493152-24-044736-index.html	Edgar Link	pending
0001493152-24-044736.txt	Edgar Link	pending
0001493152-24-044736-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
fblg-20240930.xsd	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
fblg-20240930_def.xml	Edgar Link	unprocessable
fblg-20240930_lab.xml	Edgar Link	unprocessable
fblg-20240930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
fblg-20240930_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$FBLG
FibroBiologics, Inc. Stock $fblg

2024 Q4 Form 10-Q Financial Statement

#000149315224044736 Filed on November 12, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FBLG FibroBiologics, Inc. Stock $fblg

2024 Q4 Form 10-Q Financial Statement

#000149315224044736 Filed on November 12, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FBLG
FibroBiologics, Inc. Stock $fblg